Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SOAT1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SOAT1 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Optimized for biochemical profiling. |
View SOAT1 Products |
| Gene Delivery | SOAT1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for preserving multi-pass ER membrane conformation. |
View SOAT1 Products |
| Benchmark Ab | Anti-SOAT1 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and flow cytometry. |
View SOAT1 Products |
| Validator | SOAT1 siRNA Set For knockdown verification and target specificity validation in cell-based assays. |
View SOAT1 Products |
| Related Target A | SOAT2 Crucial isoform for selectivity profiling to prevent off-target adrenal toxicity. |
View SOAT2 Products |
| Related Target B | LDLR Key downstream receptor in cholesterol homeostasis and lipid droplet regulation. |
View LDLR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ER Membrane Conformation (9-TM) | Lentivirus Premade Particles optimized for stable cell line construction, preserving native ER localization. |
| Isoform Selectivity Screening (SOAT1 vs SOAT2) | Matched SOAT1 and SOAT2 ORF expression vectors verified by sequence analysis for parallel screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control siRNAs included. |
| False Positives | High-purity reagents with strict endotoxin control (<1.0 EU/μg) to prevent non-specific cell activation. |
Live SOAT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of SOAT1 (also known as ACAT1) is expanding rapidly beyond lipid-lowering indications into oncology and neurodegenerative diseases. As an intracellular enzyme residing in the endoplasmic reticulum, SOAT1 controls the esterification of cholesterol. Inhibiting this target limits cholesteryl ester accumulation, which is critical for fueling rapid tumor growth and modulating immune cell responses in the tumor microenvironment.
The race for SOAT1 therapeutics is intensifying, with major players shifting focus from traditional systemic metabolic control to tumor-targeted small molecule inhibitors and combination immunotherapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the metabolic vulnerabilities of glioblastoma, pancreatic cancer, and Alzheimer's disease.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Millendo Therapeutics, Academic Institutions | Glioblastoma, Adrenocortical Carcinoma | Selectivity Assay (Need Mutant vs WT Proteins and SOAT2 counter-screening) |
| RNA Therapeutics / siRNA | Alnylam, Ionis Pharmaceuticals | Alzheimer's Disease, Hyperlipidemia | Target Knockdown Validation (Need validated siRNA and Lentiviral over-expression) |
| Combination Immunotherapy | Inovio, Roche | Solid Tumors (T-cell modulation) | Functional Cell-based Assays (Need stable cell line construction via Lentivirus) |